Cargando…

Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum

Preclinical evidence suggests that metformin, a widely used antidiabetic drug, may have a sensitizing effect on platinum. The purpose of this study was to evaluate the survival outcomes for non-small cell lung cancer (NSCLC) patients with type 2 diabetes mellitus (T2DM) using metformin during platin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen-Xiu, Xin, Xiao-Wei, Zheng, Hai-Ying, Ding, Ying-Hui, Tong, Si-Si, Kong, Xiao-Fang, Zhou, Huang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320173/ https://www.ncbi.nlm.nih.gov/pubmed/30572481 http://dx.doi.org/10.1097/MD.0000000000013652

Ejemplares similares

Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis
por: Xin, Wen-Xiu, et al.
Publicado: (2018)

Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy
por: Wen, Qiang, et al.
Publicado: (2017)

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
por: Liu, Jia-Si, et al.
Publicado: (2023)

Association of GWAS-Identified Lung Cancer Susceptibility Loci with Survival Length in Patients with Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Li, Dong, et al.
Publicado: (2014)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer
por: Tong, Ying-Hui, et al.
Publicado: (2017)

Cystatin C predicts the risk of incident cerebrovascular disease in the elderly: A meta-analysis on survival date studies
por: Zheng, Xin, et al.
Publicado: (2021)

Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study
por: Song, Lu-Lu, et al.
Publicado: (2020)

Colloidal hydroxyethyl starch for tumor-targeted platinum delivery
por: Xiao, Chen, et al.
Publicado: (2018)

Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
por: Fang, Shen-Cun, et al.
Publicado: (2019)

Botrychium schaffneri Underw. extract acts via DIABLO to induce apoptosis and inhibit proliferation of non-small cell lung carcinoma in vitro and in vivo
por: Liu, Yu-Jia, et al.
Publicado: (2021)

MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
por: Wang, Na, et al.
Publicado: (2018)

Correction: Association of GWAS-Identified Lung Cancer Susceptibility Loci with Survival Length in Patients with Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
Publicado: (2015)

Progress in the application and mechanism of metformin in treating non-small cell lung cancer
por: Li, Chan, et al.
Publicado: (2017)

XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer
por: Qiu, Mantang, et al.
Publicado: (2013)

High expression of monocarboxylate transporter 4 (MCT 4), but not MCT 1, predicts poor prognosis in patients with non-small cell lung cancer
por: Tong, Ying-Hui, et al.
Publicado: (2021)

Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet
por: Ryu, Jeong-Seon, et al.
Publicado: (2019)

Adjustment of Microvessel Area by Stromal Area to Improve Survival Prediction in Non-Small Cell Lung Cancer
por: Fang, Luo, et al.
Publicado: (2019)

The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: He, Jia, et al.
Publicado: (2022)

Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy
por: Zhang, Ruoxin, et al.
Publicado: (2017)

A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy
por: He, Lan, et al.
Publicado: (2021)

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015)

Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy
por: Wen, Yue-Feng, et al.
Publicado: (2018)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
por: Morgensztern, Daniel, et al.
Publicado: (2019)

Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma
por: Zheng, Shuo-Han, et al.
Publicado: (2021)

Prediction of overall survival of non-small cell lung cancer with bone metastasis: an analysis of the Surveillance, Epidemiology and End Results (SEER) database
por: Shi, Si, et al.
Publicado: (2021)

Metformin therapy associated with survival benefit in lung cancer patients with diabetes
por: Wan, Guoxing, et al.
Publicado: (2016)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
por: Chen, Ying, et al.
Publicado: (2018)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
por: Tao, Kai-Yi, et al.
Publicado: (2015)

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy
por: Brady, Anna K., et al.
Publicado: (2015)

The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non–Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy()
por: Jia, Ming, et al.
Publicado: (2016)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
por: Liu, Chang, et al.
Publicado: (2022)

Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer
por: Arrieta, Oscar, et al.
Publicado: (2016)

Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy
por: Ying, Jun, et al.
Publicado: (2019)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Platinum drugs in the treatment of non-small-cell lung cancer
por: Cosaert, J, et al.
Publicado: (2002)

NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
por: Chang, Boksoon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fv866d5bhm1vpcqijcagq2k772